North America Helicobacter Pylori Non-invasive Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

Description

List of Tables

The helicobacter pylori (H. pylori) non-invasive testing market in North America is expected to grow from US$ 211.77 million in 2022 to US$ 265.21 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2022 to 2028.

Increasing Prevalence of H. pylori Bacterial Infection Bolsters North America Helicobacter Pylori (H. pylori)

Non-invasive Testing Market

The H. pylori infection is usually developed during infancy but remains asymptomatic, with long-standing clinical symptoms, including gastritis, peptic ulcer disease, and stomach cancer. According to World Health Organization (WHO), in developed countries, the prevalence rate of H. pylori is low, i.e., 50%. Further, the prevalence of gastric disease is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Over time, aging leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining that contributes to the growing prevalence of infection among older people. According to WHO, the population of people aged 60 years and above is expected to rise. With the subsequent increase in the geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is also growing. These statistics determine the rising need for diagnostics across North America, which is expected to boost the growth of the Helicobacter pylori (H. pylori) non-invasive testing market in the region during the forecast period.

Market Overview

The North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. North America is the largest market for Helicobacter pylori (H. pylori) non-invasive testing across the globe. The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in North America. The US Department of Health and Human Services report states that ~30-40% of the population in the US suffer from H. pylori infection. Moreover, H. pylori infection is more common in the Hispanic and Black populations in the country due to socioeconomic factors, including low income, less education, household crowding, and immigration into the US. According to the ClinMed International Library report, the first-line drug regimens for the treatment of H. pylori by the Food and Drug Administration (FDA) include proton pump inhibitors (PPI) and two antibiotics or bismuth subsalicylate, acid suppressors, and two antibiotics. With approved first-line drug regimens, there exists resistance to utility. For example, the US eradication rates using these regimens accounted for 75% owing to H. pylori resistance to standard antibiotics. "Clarithromycin" and "Metronidazole" has the highest rate of resistance, and factors associated with resistance involve ethnicity, age, geographic region, and active versus inactive ulcer disease. Hence, The growing prevalence of stomach cancer, duodenal ulcers, and gastric ulcers and the development of healthcare facilities are major growth stimulators for the Helicobacter pylori (H. pylori) non-invasive testing market in the region.

North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Revenue and Forecast to 2028 (US$ Million)

North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market Segmentation

The North America helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country.

Based on test type, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market. Based on test method, the North America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022. Based on end user, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022. Based on country, the North America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into the US, Canada, and Mexico. Further, the US dominated the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in North America.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America helicobacter pylori (H. pylori) non-invasive testing market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America helicobacter pylori (H. pylori) non-invasive testing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the helicobacter pylori (H. pylori) non-invasive testing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00027539

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - By Test Type
- 1.3.2 North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market - By Test Method
- 1.3.3 North America Helicobacter Pylori (H. pylori) Non-invasive Testing Market - By End User
- 1.3.4 North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion

5. North America Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market - Key Industry Dynamics

5.1 Key Market Drivers
- 5.1.1 Increasing prevalence of H. pylori bacterial infection
- 5.1.2 New Product Launches & FDA Approvals for Noninvasive Tests
- 5.1.3 Spreading Awareness Among Individuals Regarding Diagnosis of H. pylori
- 5.1.4 Rise in Investments by Pharmaceutical Companies
5.2 Key Market Restraints
- 5.2.1 Low Diagnosis Rate
5.3 Key Market Opportunities
- 5.3.1 Increasing Number of Conferences and Events for Research
- 5.3.2 Introduction of Artificial Intelligence
5.4 Future Trends
- 5.4.1 Increasing Use of Home-Based POC Devices
- 5.4.2 Diagnosis for Resistance
5.5 Impact Analysis

6. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market- North America Analysis

6.1 North America Helicobacter pylori (H. pylori) Non-Invasive Testing Market Revenue Forecast and Analysis

7. North America Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis- by Test Type

7.1 Overview
7.2 North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By Test Type 2022 & 2028 (%)
7.3 Serology Test
- 7.3.1 Overview
- 7.3.2 North America Serology Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.4 Stool Antigen Test
- 7.4.1 Overview
- 7.4.2 North America Stool Antigen Test Market Revenue and Forecasts to 2028 (US$ Mn)
7.5 Urea Breath Test
- 7.5.1 Overview
- 7.5.2 North America Urea Breath Test Market Revenue and Forecasts to 2028 (US$ Mn)

8. North America Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis- by Test Method

8.1 Overview
8.2 North America Helicobacter pylori (H. pylori) Non-invasive Testing Market, By Test Method 2022 & 2028 (%)
8.3 Laboratory Based Tests
- 8.3.1 Overview
- 8.3.2 North America Laboratory Based Tests Market Revenue and Forecasts to 2028 (US$ Mn)
8.4 Point Of Care Tests
- 8.4.1 Overview
- 8.4.2 North America Point of Care Tests Market Revenue and Forecasts to 2028 (US$ Mn)

9. North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market Analysis- by End User

9.1 Overview
9.2 North America Helicobacter pylori (H. pylori ) Non-invasive Testing Market, By End User 2018 & 2028 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 North America Hospitals Market Revenue and Forecasts to 2028 (US$ Mn)
9.4 Clinics
- 9.4.1 Overview
- 9.4.2 North America Clinics Market Revenue and Forecasts to 2028 (US$ Mn)
9.5 Diagnostic Laboratories
- 9.5.1 Overview
- 9.5.2 North America Diagnostic Laboratories Market Revenue and Forecasts to 2028 (US$ Mn)

10. North America Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Revenue and Forecasts to 2028 - Country Analysis

10.1 Overview
- 10.1.1 North America: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Country, 2022 & 2028 (%)
  - 10.1.1.1 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.1.3 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020-2028 (US$ Million)
    - 10.1.1.1.4 US: Helicobacter Pylori (H. pylori) Non-invasive Testing Market, by Test Method, 2020-2028 (US$ Million)
    - 10.1.1.1.5 US: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020-2028 (US$ Million)
  - 10.1.1.2 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.2.3 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020-2028 (US$ Million)
    - 10.1.1.2.4 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method, 2020-2028 (US$ Million)
    - 10.1.1.2.5 Canada: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020-2028 (US$ Million)
  - 10.1.1.3 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.3.3 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Type, 2020-2028 (US$ Million)
    - 10.1.1.3.4 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by Test Method, 2020-2028 (US$ Million)
    - 10.1.1.3.5 Mexico: Helicobacter Pylori (H. pylori ) Non-invasive Testing Market, by End User, 2020-2028 (US$ Million)

11. Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profile

12.1 DiaSorin S.p.A.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Meridian Bioscience, Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 QuidelOrtho Corporation
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Abbott Laboratories
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 CerTest Biotec
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Sekisui Diagnostics
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Coris BioConcept
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Bio-Rad Laboratories, Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms